Altshuler Shaham’s Evogene EVGN Stock Holding History

Altshuler Shaham’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-750	Closed	-$825	–	453
2025 Q4	$825	Hold	750	–	–	﹤0.01%	388
2025 Q3	$856	Buy	+750	New	+$950	﹤0.01%	357
2019 Q2	–	Sell	-8,673	Closed	-$152K	–	372
2019 Q1	$152K	Hold	8,673	–	–	0.01%	105
2018 Q4	$180K	Hold	8,673	–	–	0.01%	110
2018 Q3	$258K	Hold	8,673	–	–	0.01%	103
2018 Q2	$249K	Hold	8,673	–	–	0.02%	100
2018 Q1	$272K	Hold	8,673	–	–	0.04%	103
2017 Q4	$283K	Buy	+8,673	New	+$341K	0.04%	88

Other funds holding EVGN

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

DSC

Daytona Street Capital Saint Louis, Missouri $130M AUM

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Altshuler Shaham's EVGN Position: Q1 2026 in Review

Altshuler Shaham sold out of Evogene (EVGN) in Q1 2026, closing a stake of 750 shares — an estimated $825 sold.

Altshuler Shaham first reported a position in EVGN in Q4 2017 and held it in 8 quarters. The position peaked at $283K in Q4 2017. 15 funds tracked by Wall St. Rank hold EVGN as of Q1 2026.

Altshuler Shaham reported no remaining Evogene position as of Q1 2026 after selling out during the quarter.
Altshuler Shaham sold 750 Evogene shares in Q1 2026, an estimated $825.
Altshuler Shaham first reported a position in Evogene in Q4 2017 and held it in 8 quarters.
Altshuler Shaham's Evogene position peaked at $283K in Q4 2017.
15 funds tracked by Wall St. Rank held Evogene as of Q1 2026.

Based on Altshuler Shaham's 13F filing for Q1 2026, filed 18 May 2026.